Should I Buy MLYS? MLYS 2026 Analysis

Should You Buy Mineralys Therapeutics Inc (MLYS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

29.770

1 Day change

5.53%

52 Week Range

47.650

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: momentum is still bearish (MACD histogram below 0 and worsening) and price is slipping under near-term support.
If you already own it, this is more of a hold/monitor for a bounce setup near support rather than an add-today setup.
Upside is fundamentally/strategically driven (partnering, regulatory progress) and analysts are bullish, but there is no near-term catalyst/news this week to force an immediate reversal.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend/momentum: Bearish near-term. MACD histogram is negative (-0.0544) and negatively expanding, implying downside momentum is still building.
RSI: RSI_6 at 27.545 suggests the stock is oversold/washed out on a very short lookback, which can support a dead-cat bounce, but it’s not a confirmed reversal signal by itself.
Moving averages: Converging MAs = indecision/transition, but with MACD worsening, bias remains down until price reclaims key levels.
Key levels:
- Pivot: 31.74 (regaining this would improve short-term structure)
- Resistance: 33.62 (R1) then 34.78 (R2)
- Support: 29.86 (S1) (price is slightly below this at 29.62) and 28.70 (S2) as the next downside level.
Pattern-based forward look (model on similar candlesticks): ~50% chance of -0.34% next day, -0.11% next week, but +29.11% next month (suggests volatility and potential mean reversion, not immediate strength).

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning (Open Interest): Put/Call OI ratio 1.71 is bearish/defensive, implying more outstanding put positioning (hedging or bearish bets).
Flow (Volume): Put/Call volume ratio 0.86 is slightly call-leaning/neutral, suggesting today’s traded flow isn’t strongly bearish.
Volatility: 30D IV 95.14% vs historical vol 47.96% = options are pricing very large moves (event/speculation premium). IV percentile 48.21 is mid-range; IV rank 10 suggests current IV is not at the top of its recent range.
Activity: Volume today vs 30D avg 1.62x (elevated), but absolute contract volume is small (80 total), so sentiment read is limited.

Technical Summary

Sell

Buy

Positive Catalysts

- Company progress narrative (per analysts): advancing toward near-term application submission for lorundrostat (regulatory milestone potential).

Neutral/Negative Catalysts

- No news/catalyst in the past week to spark immediate upside; price action is currently being driven by bearish momentum.
- Technical momentum remains down (MACD worsening) and price is below/near support, raising risk of a flush toward 28.70.
- Options OI skew (P/C 1.71) signals meaningful hedging/bearish positioning overhang.
- Biopharma profile with no revenue: valuation is highly sentiment/catalyst-dependent; without a near-term event, the stock can drift or slide.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 0 (pre-revenue profile).
Profitability: Net income -36.93M, down 34.45% YoY (loss widened).
EPS: -0.52, down 53.98% YoY.
Takeaway: Financials reflect a development-stage biotech with increasing losses, so the stock needs execution/catalysts (trial/regulatory/partnering) rather than operating leverage to drive near-term upside.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst actions are uniformly positive (all Buy maintained) with price target raises:
- Stifel (2025-12-19): PT raised to $52 from $45, Buy.
- BofA (2025-12-19): PT raised to $46 from $43, Buy; highlights partnering as a major value-maximizing catalyst.
- H.C. Wainwright (2025-11-12): PT raised to $56 from $52, Buy; upbeat on approaching application submission.
Wall Street pros: Strong upside-to-targets from current price (~29.62) and clear catalyst roadmap (submission/partner).
Wall Street cons: Bull case depends on execution and partnering; without near-term catalysts, the stock can remain technically weak despite bullish targets.

6 Analyst Rating

Wall Street analysts forecast MLYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLYS is 52.6 USD with a low forecast of 46 USD and a high forecast of 56 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 28.210

Low

Averages

52.6

High

Current: 28.210

Low

Averages

52.6

High

Stifel

Buy

maintain

$45 -> $52

AI Analysis

2025-12-19

Reason

Stifel

Price Target

$45 -> $52

AI Analysis

2025-12-19

maintain

Buy

Reason

Stifel raised the firm's price target on Mineralys Therapeutics to $52 from $45 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst's Biopharma coverage.

BofA

Buy

maintain

$43 -> $46

2025-12-19

Reason

BofA

Price Target

$43 -> $46

2025-12-19

maintain

Buy

Reason

BofA raised the firm's price target on Mineralys Therapeutics to $46 from $43 and keeps a Buy rating on the shares after the company reported Q3 results and guided for a cash runway into 2027. A "major potential catalyst" would be Mineralys finding a commercialization and development partner, which the firm views as "necessary to maximize value," the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MLYS

Unlock Now

MLYS Should I Buy

MLYS Should I Buy

Should You Buy Mineralys Therapeutics Inc (MLYS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch